SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

Metformin, a widely used and affordable diabetes drug, could prevent a form of acute myeloid leukemia in people at high risk ...

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

Sellas (NASDAQ:SLS) reported positive data from a Phase 2 study of its drug SLS009 in the treatment of patients with relapsed/refractory acute myeloid leukemia, or AML, with ASXL1 mutations.

“The most anticipated milestones in 2025 will be the final analysis of our Phase 3 pivotal REGAL trial of GPS in acute myeloid ... AML patients with myelodysplasia-related changes (AML MRC ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009, a ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia ... in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML ... in AML patients with myelodysplasia-related changes (AML ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia-related cytogenetics). 4 of those patients had myelomonocytic phenotype (M4 per FAB classification). The ...